BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home » Blogs » BioWorld MedTech Perspectives » Coverage of coverage: two recent moves by CMS

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Coverage of coverage: two recent moves by CMS

Nov. 7, 2013
By Mark McCarty

Continental_Currency_One-Third-Dollar_17-Feb-76_obv
A third of a dollar isn't what it used to be, is it?

When it comes to coverage and reimbursement, there are gatekeepers all over the place, but some keep bigger gates than others. Following are two stories about the Centers for Medicare & Medicaid Services and how it has kept its gate in recent weeks.

CMS not wild about MILD

CMS recently took it upon itself to review percutaneous, image-guided lumbar decompression for stenosis, proposing on Oct. 17 that it sees the evidence as insufficient to prompt coverage.

Among the references found in the coverage proposal is one addressing the MILD procedure by Vertos Medical, a company that is no doubt pulling out all the stops to get CMS on board. The agency said most of the evidence in support was provided by case series, and the only randomized, controlled trial “had a small enrollment and major design flaws.”

CMS also said it has “questions about missing information, questions about adverse events and conflicts of interest,” concluding that the evidence “does not support a conclusion of improved health outcomes.”

So it doesn’t look good. Still, we might bear in mind that more than 100 people sounded off on the treatment, the vast majority of which were supportive. Even if CMS passes, this won’t be the last we hear of MILD and PILD.

Heart failure? VAD you asked

CMS also recently published a coverage memo for ventricular assist devices, which among other things declared the Intermacs registry a dinosaur. The problem here is that the age of mammals has yet to arrive where a replacement registry is concerned, so T. Rex reigns until further notice.

Perhaps the most significant aspect of this coverage memo is that CMS seems to have pried open enough space for those bridge-to-decision patients with a passage stating that the agency has removed the word “permanent” from the language dealing with VAD for destination therapy.

Doctors seem to be of the view that CMS left a lot of ambiguity in its rewrite of the coverage manual, and the term “destination therapy” will now include a much more varied population. Still, where there’s fuzziness, there’s latitude, and what was a bad state of limbo for some heart failure patients now becomes a haven, and the docs have to deal with limbo, which frankly is a task they’re paid to handle.

All in all, it sounds like an improvement for heart failure patients, and an especially welcome bit of news for a patient population that is in desperate straits.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 13, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing